Erubin2 mg/ml

Erubin is a cytotoxic anthracycline antibiotic used in cancer chemotherapy, almost always as part of a combination regimen.

Established / FDA-approved use

• As a component of adjuvant chemotherapy in patients with early breast cancer who have evidence of axillary lymph node involvement following surgical resection of the primary tumor, typically combined with other agents such as cyclophosphamide and fluorouracil.

Guideline-supported / widely used combination-regimen indications

• Metastatic or advanced breast cancer, as part of combination chemotherapy.
• Advanced gastric (stomach) cancer, in combination regimens (e.g., with cisplatin and fluorouracil).

Off-label uses (less common, individualized by an oncologist)

• Selected soft-tissue sarcomas, ovarian cancer, and certain lymphomas, when used by specialists as part of protocol-based combination chemotherapy.
• Intravesical (bladder instillation) use for superficial (non-muscle-invasive) bladder cancer or carcinoma in situ, and for prophylaxis after resection, in specific formulations intended for this route.

Erubin must only be prescribed and administered by, or under the supervision of, a physician experienced in the use of cytotoxic chemotherapy.

Each vial/formulation of Epirubicin Hydrochloride contains Epirubicin Hydrochloride as the active pharmaceutical ingredient, supplied either as a sterile lyophilized powder for reconstitution or as a preservative-free, ready-to-use sterile solution for intravenous (or, for specific formulations, intravesical) administration.

Erubin is a semisynthetic anthracycline cytotoxic antibiotic derived from Streptomyces peucetius var. caesius. It is the 4'-epimer of doxorubicin and belongs to the anthracycline class of antineoplastic agents.

Erubin works by intercalating into DNA and inhibiting the enzyme topoisomerase II, leading to disruption of DNA replication and transcription and ultimately cell death. Because it is a potent cytotoxic (cell-killing) agent, it is used exclusively in cancer chemotherapy under specialist supervision, and carries significant boxed warnings for cardiac and bone marrow toxicity.

Anthracycline cytotoxic antineoplastic agent (topoisomerase II inhibitor)

Epirubicin Hydrochloride exerts its antitumor effect through several mechanisms: it intercalates between DNA base pairs, inhibits topoisomerase II (causing DNA strand breakage), and generates cytotoxic free radicals that damage DNA and cell membranes. These actions interfere with DNA and RNA synthesis and lead to apoptosis of rapidly dividing cells, including tumor cells.

Following intravenous administration, Epirubicin Hydrochloride is widely distributed into tissues, extensively metabolized in the liver (mainly to epirubicinol and glucuronide conjugates), and eliminated primarily via biliary/fecal excretion, with a smaller fraction excreted renally. Because hepatic metabolism is the principal clearance pathway, dose adjustment is required in patients with hepatic impairment.

Erubin is administered only by intravenous injection or infusion (and, for certain formulations, by intravesical instillation into the bladder) by trained healthcare personnel using proper cytotoxic handling precautions (protective equipment, safe disposal).

• Given as a slow intravenous injection into a free-flowing intravenous line, or as a short intravenous infusion, over several minutes.
• Erubin is a vesicant; extreme care must be taken to avoid extravasation (leakage into surrounding tissue), which can cause severe local tissue damage and necrosis. The infusion is stopped immediately if extravasation is suspected.
• Must not be given by the intramuscular, subcutaneous, or intrathecal route; intrathecal administration has resulted in serious injury and death.
• Personnel preparing or administering Erubin should avoid skin/eye contact and follow institutional guidelines for handling cytotoxic drugs.

Erubin has several clinically important drug interactions that must be reviewed by the treating oncologist:

• Other cardiotoxic agents (e.g., trastuzumab, other anthracyclines, high-dose cyclophosphamide): Concurrent or sequential use increases the risk of cardiotoxicity/heart failure; cardiac function should be closely monitored, and combined cumulative anthracycline exposure must be tracked (see Precautions and Warnings).
• Cimetidine: Increases plasma concentration and reduces clearance of Erubin, potentially increasing toxicity; concurrent use should be avoided or cimetidine discontinued during Erubin treatment.
• Other myelosuppressive drugs or radiotherapy: Additive bone marrow suppression; blood counts require closer monitoring when Erubin is combined with other agents that suppress the bone marrow, or given with radiotherapy fields that include the bone marrow or heart.
• Live or live-attenuated vaccines: Should be avoided during and for a period after Erubin therapy because of the risk of severe or disseminated infection due to immunosuppression.
• Paclitaxel: If administered before Erubin, can increase plasma concentrations of Erubin and its metabolites; the two are generally sequenced to minimize this interaction.

Side effects of Erubin are frequent and dose-related, given that it is a potent cytotoxic chemotherapy agent. Report any severe or persistent symptom to your treating team immediately.

Very common

• Myelosuppression (low white blood cells, anemia, low platelets) — increases infection and bleeding risk.
• Nausea, vomiting, mucositis/stomatitis, diarrhea.
• Alopecia (hair loss), usually reversible after treatment ends.
• Amenorrhea (in women) and effects on fertility.
• Reddish discoloration of urine for 1–2 days after administration (expected, not harmful).

Serious (require prompt medical attention)

• Signs of heart failure/cardiotoxicity (shortness of breath, swelling of legs, irregular heartbeat) — see Precautions and Warnings.
• Severe or prolonged fever, chills, or signs of infection due to low white cell counts.
• Injection-site pain, redness, or tissue damage from extravasation.
• Signs of secondary blood cancers (unusual bruising, persistent fatigue), which can occur months to years after treatment — see Precautions and Warnings.

Erubin can cause fetal harm and is strictly avoided during pregnancy, especially in the first trimester. Women of childbearing potential should use effective contraception during, and for a period after, treatment with Erubin, and men receiving Erubin should also use effective contraception. If Erubin is used during pregnancy, or if the patient becomes pregnant during treatment, she should be informed of the potential risk to the fetus. Use only if the treating oncologist judges it clearly necessary and unavoidable, after full discussion of risks; consult a physician.

Erubin is excreted into breast milk; breastfeeding must be discontinued before starting treatment and should not be resumed without explicit medical advice, given the risk of serious adverse effects in the nursing infant.

Boxed warnings

• Cardiotoxicity: Erubin can cause cumulative, dose-related cardiac toxicity, including congestive heart failure, which may occur during therapy or be delayed by months to years after completion of treatment. Risk rises sharply as the lifetime cumulative dose increases; baseline and periodic monitoring of left ventricular ejection fraction (LVEF) is required, and a lifetime cumulative dose limit must be respected.
• Myelosuppression: Severe bone marrow suppression is expected and can be life-threatening; complete blood counts must be monitored before and during each cycle.
• Secondary leukemia: Treatment-related acute myeloid leukemia/myelodysplastic syndrome can occur, particularly with higher cumulative doses or when combined with other DNA-damaging agents or radiotherapy.
• Extravasation/tissue necrosis: Erubin is a vesicant; extravasation can cause severe local tissue injury requiring surgical debridement. It must be given only into a securely, freely running intravenous line.
• Erubin must be administered only under the supervision of a physician experienced in the use of cytotoxic chemotherapeutic agents, in a facility equipped to manage complications.

Other precautions

• Dose reduction is required in hepatic impairment (see Dosage and Administration); liver function should be assessed before each cycle.
• Tumor lysis syndrome can occur in patients with large tumor burdens; monitor renal function and electrolytes.
• Radiation recall reactions can occur at sites of previous irradiation.
• Vaccination with live vaccines should be avoided during therapy (see Interactions).

Overdose of Erubin can cause severe, potentially fatal myelosuppression (typically within 10–14 days), severe mucositis/gastrointestinal toxicity, and acute cardiac toxicity (which can occur within 24 hours of a marked overdose). Because Erubin is administered in a hospital/clinic setting, suspected overdose should be treated as a medical emergency: seek immediate medical attention and contact the treating oncology unit or emergency services right away. Treatment is supportive and typically includes hospitalization, blood count monitoring with transfusion support, antibiotics for infection, symptomatic management of mucositis, and intensive cardiac monitoring; there is no specific antidote. Do not attempt any home treatment for a suspected overdose.

Store in a refrigerator (2°C–8°C), protected from light, in the original carton until the time of use. Do not freeze the ready-to-use solution. Keep out of reach of children. Handle and dispose of as a cytotoxic medicine according to institutional guidelines.

Hepatic impairment

Dose reduction of Erubin is required in patients with elevated bilirubin or liver enzymes, as hepatic impairment significantly increases systemic exposure and toxicity; Erubin is contraindicated in severe hepatic impairment (see Contraindications).

Renal impairment

Renal excretion is a minor elimination pathway; formal dose adjustment guidelines for renal impairment are not well established, but caution and closer monitoring are advised in significant renal impairment.

Elderly

Older patients may be at greater risk of cardiotoxicity and severe myelosuppression; closer monitoring of cardiac function and blood counts is recommended.

Pediatric patients

Safety and efficacy of Erubin have not been established in pediatric patients; see Pediatric Uses.

Erubin is given in cycles, typically every 3 to 4 weeks, as part of a multi-drug chemotherapy protocol. The total number of cycles (commonly 4 to 8 in adjuvant breast cancer regimens) and overall treatment duration are determined by the treating oncologist, based on the specific protocol, cancer stage, response to treatment, and tolerance/toxicity, always respecting the lifetime cumulative dose limit for Erubin to reduce the risk of cardiotoxicity.

For lyophilized powder formulations of Erubin, reconstitute with sterile Water for Injection or 0.9% Sodium Chloride Injection to achieve a concentration of approximately 2 mg/mL, following the manufacturer's product-specific instructions. The reconstituted solution should be inspected visually for particulate matter and discoloration before use, and used within the manufacturer-specified time when stored under refrigeration, protected from light. Preparation should be performed by trained personnel using cytotoxic-safe handling techniques (gloves, eye protection, biological safety cabinet). Ready-to-use liquid formulations of Erubin do not require reconstitution and should simply be diluted (if directed) before administration.

Anthracyclines; Topoisomerase II inhibitors; Cytotoxic antineoplastic (chemotherapy) agents

Epirubicin Hydrochloride intercalates between DNA base pairs and binds to topoisomerase II, stabilizing the DNA-topoisomerase II cleavable complex and preventing re-ligation of DNA strand breaks; it also generates reactive oxygen species (free radicals) that damage DNA, proteins, and cell membranes. The net effect is inhibition of DNA and RNA synthesis, cell-cycle arrest, and apoptosis, which is particularly pronounced in rapidly dividing tumor cells, but also affects rapidly dividing normal cells such as bone marrow and hair follicle cells (accounting for its main toxicities).

D

The safety and efficacy of Erubin have not been established in pediatric patients; it is not approved for routine use in children. Use in pediatric oncology, when it occurs, is limited to specialized pediatric oncology protocols under the direct supervision of a pediatric oncologist, with intensive monitoring for cardiotoxicity and myelosuppression, given the heightened long-term risk of cardiac damage in children who receive anthracyclines.